Last reviewed · How we verify
Gan & Lee Insulin Glargine Injection
Insulin glargine is a long-acting basal insulin that binds to insulin receptors to lower blood glucose by promoting glucose uptake and storage in peripheral tissues and suppressing hepatic glucose production.
Insulin glargine is a long-acting basal insulin that binds to insulin receptors to lower blood glucose by promoting glucose uptake and storage in peripheral tissues and suppressing hepatic glucose production. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Gan & Lee Insulin Glargine Injection |
|---|---|
| Sponsor | Gan and Lee Pharmaceuticals, USA |
| Drug class | Long-acting basal insulin |
| Target | Insulin receptor |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Insulin glargine is a recombinant human insulin analog engineered with amino acid substitutions to provide a prolonged, peakless duration of action (up to 24 hours). It binds to the insulin receptor on muscle, adipose, and liver cells, facilitating glucose uptake and glycogen synthesis while inhibiting gluconeogenesis and lipolysis. This basal insulin replacement therapy is used to maintain fasting and between-meal glucose control in diabetes.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
- Gan & Lee Insulin Glargine Target Type (1) Evaluating Research (PHASE3)
- Gan & Lee Insulin Glargine Target Type (2) Evaluating Research (PHASE3)
- PK/PD Biosimilarity Study of Gan & Lee Insulin Glargine Injection vs.US & EU Lantus® in Type 1 Diabetes Mellitus Patients (PHASE1)
- PK/PD Study of Gan & Lee's Insulin Glargine Injection in Comparison to Lantus in Type 1 Diabetes (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: